Selvom carcinogenicitetspotentialet hos mennesker ikke er kendt, antyder disse data at efavirenz kliniske fordele opvejer den mulige carcinogenicitet hos mennesker.
While the carcinogenic potential in humans is unknown, these data suggest that the clinical benefit of efavirenz outweighs the potential carcinogenic risk to humans.